Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical effect of Jianpi Lishi Jiedu Decoction on postoperative patients with spleen deficiency and dampness toxin type colorectal adenoma

ABSTRACT: Interventions: The experimental group:Chinese medicine Jianpi Lishi Jiedu recipe, twice a day, 25ml each time, 1 hour after breakfast and dinner, course of 3 months;The control group:Follow up and observation Primary outcome(s): Main symptoms of Patiens;Curative effect of TCM Syndrome;Recurrence rate of colorectal adenoma;Safety indicators (such as routine hematuria feces, liver and kidney function, ECG);Beta-catenin Study Design: Parallel

DISEASE(S): Colorectal Adenoma

PROVIDER: 2704459 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Efficacy and safety of Jianpi Bushen Decoction on the chemotherapy induced myelosuppression in patients with colorectal cancer: a randomized controlled trial

Project description:Interventions: TCM and chemotherapy:Jianpi Bushen Decoction combined with chemotherapy;Chemotherapy:Chemotherapy Primary outcome(s): Peripheral blood leukocytes Study Design: Randomized parallel controlled trial

| 2675741 | ecrin-mdr-crc

Therapeutic Effect and Mechanism of Bushen-Jianpi-Jiedu Decoction Combined with Chemotherapeutic Drugs on Postoperative Colorectal Cancer.

Project description:There is a lack of effective therapeutic drugs in patients with postoperative colorectal cancer (PCRC). This study aimed to investigate the therapeutic effect and mechanisms of Bushen-Jianpi-Jiedu decoction (BSJPJDD) combined with chemotherapeutic drugs (oxaliplatin) on PCRC with liver and kidney yin deficiency and spleen deficiency syndrome (LKYD-SDS) through the therapeutic evaluation of clinical therapy and the integrative analysis of network pharmacology, RNA-seq and label-free data, and experiment verification in vitro. In clinical therapy, the median progression-free survival (PFS) and Karnofsky performance score (KPS) were increased in PCRC patients by the aqueous extract of BSJPJDD combined with oxaliplatin treatment for three months, compared to oxaliplatin alone (p < 0.05). The integrative analysis showed that 559 differentially expressed genes (DEGs) and 11 differentially expressed proteins (DEPs) were regulated by BSJPJDD, among which seven bioactive compounds through 39 potential targets were involved in the regulation of multiple signaling pathways including MAPK, PI3K-Akt, and HIF-1, etc. In the experimental verification, an ELISA assay showed that plasma ZEB2, CAT, and KRT78 were decreased, and IL-1Α, CD5L, FBLN5, EGF, and KRT78 were increased in comparison to the above (p < 0.05). Furthermore, the SW620 cell viability was inhibited and the expressions of MAPK and the p-ERK/ERK ratio were significantly downregulated by the aqueous extract of BSJPJDD combined with oxaliplatin treatment, compared with oxaliplatin treatment alone (p < 0.05). These data suggested that BSJPJDD combined with oxaliplatin prolongs the survival and improves Karnofsky performance status of PCRC patients with LKYD-SDS, and may be associated with the regulation of multiple signaling pathways.

| S-EPMC8020259 | biostudies-literature

Effect of Jianpi Huatan Decoction on Advanced Colorectal Cancer

Project description:This study will take progression-free survival and overall survival as the main evaluation indexes, to evaluate the Efficacy of Jianpi Huatan Decoction in the Treatment of Advanced Colorectal Cancer. Decision Trees and Discriminant Analysis will be used to analyze the characteristics of dominant population combined with clinical data of patients. DNA methylation of the subjects will be detected to study the methylation characteristics of the preponderant population of Jianpi Huatan Decoction.

| 2400655 | ecrin-mdr-crc

Jianpi Jiedu decoction reverses 5-fluorouracil resistance in colorectal cancer by suppressing the xCT/GSH/GPX4 axis to induce ferroptosis.

Project description:IntroductionInnate and acquired chemoresistance in colorectal cancer (CRC) often results in 5-fluorouracil (5-FU) treatment failure. This study aimed to investigate the potential of Jianpi Jiedu (JPJD) decoction to reverse 5-FU resistance in CRC and clarify its potential mechanism of action.MethodsThe CCK-8 assay was employed to assess cell activity. Flow cytometry was employed to assess various parameters including cell apoptosis, cell cycle distribution, P-glycoprotein (P-gp) activity, reactive oxygen species levels, and lipid peroxidation. Metabolomics analysis was conducted to identify differentially expressed metabolites. Western blotting was utilized for protein expression analysis.ResultsIn this study, we demonstrated that the combined JPJD and 5-FU treatment reversed 5-FU resistance in HCT8/5-FU cells, inducing cell apoptosis, causing G2/M-phase cell cycle arrest, and reducing P-gp protein expression and activity. Metabolomics analysis revealed ferroptosis as a key pathway in the development of 5-FU resistance. Furthermore, the combination treatment reversed drug resistance primarily by impacting ferroptosis and triggering critical ferroptosis events through the suppression of the cystine/glutamate transporter (xCT)/glutathione (GSH)/glutathione peroxidase (GPX4) axis.ConclusionJPJD decoction primarily suppressed the xCT/GSH/GPX4 axis to trigger ferroptosis, thereby effectively reversing 5-FU resistance in colorectal cancer (CRC).

| S-EPMC10918199 | biostudies-literature

Protective effect of Jianpi Qinghua Sanyu Yin (JPQHSYY) on raised erosive gastritis (REG) [ncRNA-Seq]

Project description:This study aims to comparatively analyze the differentially expressed lncRNA in tissue samples from patients with Raised Erosive Gastritis (REG), before and after treatment with Jianpi Qinghua Sanyu Decoction (JPQHSYY).

2025-03-01 | GSE289594 | GEO

Protective effect of Jianpi Qinghua Sanyu Yin (JPQHSYY) on raised erosive gastritis (REG) [miRNA-Seq]

Project description:This study aims to comparatively analyze the differentially expressed small RNA in tissue samples from patients with Raised Erosive Gastritis (REG), before and after treatment with Jianpi Qinghua Sanyu Decoction (JPQHSYY).

2025-03-01 | GSE289593 | GEO

Multi-omics analysis reveals Jianpi formula-derived bioactive peptide-YG-22 potentially inhibited colorectal cancer via regulating epigenetic reprogram and signal pathway regulation [RNA-Seq]

Project description:Colorectal cancer (CRC) is a prevalent malignancy worldwide, often treated with chemotherapy despite its limitations, including adverse effects and resistance. Chemotherapy combined with the traditional Chinese medicine (TCM) Jianpi formula has been demonstrated to improve efficacy. In this study, we aim to screen bioactive peptides derived from the blood of CRC patients through peptidomics and explore the molecular mechanisms of the candidate peptides in HCT116 cells using multi-omics analysis. Differential peptides were identified in plasma samples from patients treated with chemotherapy alone and those receiving the combined therapy. Among these, YG-22 exhibited the strongest cytotoxic effect on HCT116 cells, reducing viability in a dose- and time-dependent manner. Transcriptome analysis highlighted the modulation of key pathways involved in lysosome-mediated degradation and apoptosis, while metabolomic profiling indicated disruptions in tumor-supportive metabolic pathways. Additionally, chromatin accessibility and histone modifications suggested epigenetic reprogramming induced by YG-22. These findings demonstrate that combining chemotherapy with TCM enriches the molecular landscape and generates bioactive peptides with strong antitumor activity. Furthermore, this study also lays the foundation for further development of peptide-based therapies and highlights the value of combining traditional and modern therapeutic strategies for CRC management.

2025-03-26 | GSE289008 | GEO

Multi-omics analysis reveals Jianpi formula-derived bioactive peptide-YG-22 potentially inhibited colorectal cancer via regulating epigenetic reprogram and signal pathway regulation [ChIP-Seq]

2025-03-26 | GSE289007 | GEO

Multi-omics analysis reveals Jianpi formula-derived bioactive peptide-YG-22 potentially inhibited colorectal cancer via regulating epigenetic reprogram and signal pathway regulation [ATAC-seq]

2025-03-26 | GSE289006 | GEO

Yiqi Jianpi Huayu Jiedu Decoction Inhibits Metastasis of Colon Adenocarcinoma by Reversing Hsa-miR-374a-3p/Wnt3/β-Catenin-Mediated Epithelial-Mesenchymal Transition and Cellular Plasticity.

Project description:Colon adenocarcinoma (COAD) accounts for 95% of colon cancer cases, with the 5-year survival rate significantly affected by local or distant metastases. Yiqi Jianpi Huayu Jiedu decoction (YJHJD), based on the theory of "nourish qi, invigorate the spleen, remove blood stasis, and detoxify", has long been applied and shown to be remarkable in the prevention and treatment of gastrointestinal tumors. However, the underlying therapeutic mechanisms of YJHJD have not been fully elucidated. Herein, we first confirmed hsa-miR-374a-3p as a tumor suppressor based on its lower expression in the plasma of patients with COAD with liver metastasis and association with more advanced local progression. We also verified WNT3 as a potential target of hsa-miR-374a-3p and observed its increased expression in COAD tissues. Furthermore, we showed that the hsa-miR-374a-3p/Wnt3/β-catenin axis was responsible for epithelial-mesenchymal transition (EMT) and cellular plasticity in COAD, as well as poorer patient prognosis. Our results showed that YJHJD inhibited motility and colony potential in vitro, as well as liver metastasis of COAD in vivo. Moreover, YJHJD induced a reversal of EMT and cellular plasticity-related molecular expression, increased hsa-miR-374a-3p, and decreased Wnt3 and β-catenin levels. In addition, silencing of hsa-miR-374a-3p weakened YJHJD inhibition, whereas the β-catenin inhibitor XAV939 partially repaired it. Taken together, these results demonstrated that YJHJD suppressed the EMT and cellular plasticity of COAD by regulating hsa-miR-374a-3p/Wnt3/β-catenin signaling.

| S-EPMC9273741 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data